DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Depen (Penicillamine) - Summary

 
 



Physicians planning to use penicillamine should thoroughly familiarize themselves with its toxicity, special dosage considerations, and therapeutic benefits. Penicillamine should never be used casually. Each patient should remain constantly under the close supervision of the physician. Patients should be warned to report promptly any symptoms suggesting toxicity.

 

DEPEN SUMMARY

DEPENĀ®
(penicillamine tablets, USP)
Titratable Tablets

Penicillamine is 3-mercapto-D-valine, a disease modifying antirheumatic drug. It is a white or practically white, crystalline powder, freely soluble in water, slightly soluble in alcohol, and insoluble in ether, acetone, benzene, and carbon tetrachloride. Although its configuration is D, it is levorotatory as usually measured.

DEPEN is indicated in the treatment of Wilson's disease, cystinuria, and in patients with severe, active rheumatoid arthritis who have failed to respond to an adequate trial of conventional therapy. Available evidence suggests that DEPEN is not of value in ankylosing spondylitis.
See all Depen indications & dosage >>

NEWS HIGHLIGHTS

Media Articles Related to Depen (Penicillamine)

Amputation May Not Independently Predict Mortality in Diabetes
Source: Medscape Diabetes & Endocrinology Headlines [2016.06.21]
In a 22-year study of male veterans with diabetes, foot ulcer and PAD independently predicted mortality, whereas amputation did not. Amputation can often improve quality of life, says one expert.
Medscape Medical News

Time-Dependent Effects of Cardiovascular Exercise on Memory
Source: Medscape Orthopaedics Headlines [2016.06.20]
Find out more about the relationship between cardiovascular exercise and memory processing -- and learn how the timing of exercise may impact the effects.
Exercise and Sport Sciences Reviews

FDA approves first buprenorphine implant for treatment of opioid dependence
Source: Alcohol / Addiction / Illegal Drugs News From Medical News Today [2016.05.27]
Expanded use and availability of medication-assisted treatment is a top priority of federal effort to combat opioid epidemic.The U.S.

Severe stroke prognoses differ depending on the doctor
Source: Rehabilitation / Physical Therapy News From Medical News Today [2016.05.09]
A physician has to make many quick decisions when confronted with a stroke patient.Should treatment be intensive or comfort-based, or somewhere in between?

Empowering people with incontinence and their carers to live independent and dignified lives at home and in the community
Source: Caregivers / Homecare News From Medical News Today [2016.04.27]
Study conducted in six European regions contributes to better understanding of how to improve thecare for people with incontinence in their daily lives at home and in the community.

more news >>

Published Studies Related to Depen (Penicillamine)

Oral D-penicillamine for the prevention of retinopathy of prematurity in very low birth weight infants: a randomized, placebo-controlled trial. [2010.09]
PURPOSE: To compare prophylactic enteral D-penicillamine (DPA) with placebo for prevention of 'retinopathy of prematurity (ROP) or death' among very low birth weight (VLBW) infants... CONCLUSION: Prophylactic enterally administered DPA suspension in a dose 100 mg/kg/dose 8 h for 3 days, followed by 50 mg/kg once per day for next 11 days, does not prevent 'any stage ROP or death' or 'ROP requiring treatment' in VLBW infants. DPA is well tolerated and does not have any major short-term adverse effects. (c) 2010 The Author(s)/Journal Compilation (c) 2010 Foundation Acta Paediatrica.

Oral D-penicillamine for the prevention of retinopathy of prematurity in very low birth weight infants: a randomized, placebo-controlled trial. [2010.04.16]
Abstract Purpose: To compare prophylactic enteral D-penicillamine (DPA) with placebo for prevention of 'retinopathy of prematurity (ROP) or death' among very low birth weight (VLBW) infants. Methods: This was a double-blind, single-centre, randomized, placebo-controlled trial with stratification (for birth weight <1250 and >/=1250 g) and blocking...

D-Penicillamine for preventing retinopathy of prematurity in preterm infants. [2013]
CONCLUSIONS: Administration of prophylactic D-penicillamine in preterm

D-penicillamine, a potent melanogenesis inhibitor, lacks any depigmenting effect on black guinea pig skin: the first randomized, evaluator-blinded, vehicle-controlled, in vivo study. [2011.06]
D-penicillamine is a melanogenesis inhibitor. This in vivo study on ten black guinea pigs using a 5% D-penicillamine ointment showed its lack of any skin-lightening effect.The potential reasons for this ineffectiveness are discussed in the paper, which could be very helpful for researchers exploring new skin-lightening agents.

D-penicillamine elastosis perforans serpiginosa: description of two cases and review of the literature. [2011.04.15]
Long term D-penicillamine (DPA) therapy to treat Wilson disease can induce elastosis perforans serpiginosa (EPS), a very rare degenerative skin disease characterized by a transepidermal elimination of elastic fiber aggregates.

more studies >>

Clinical Trials Related to Depen (Penicillamine)

Post Marketing Surveillance Study of Cuprimine [No longer available]
Cuprimine (penicillamine) was made available in the Philippines by the Sponsor under a Compassionate Special Permit issued by the Bureau of Food and Drugs. Physicians were able to request the drug for their patients from the Sponsor. A Clinical Study Report form was completed for each purchase of Cuprimine.

Penicillamine, Low Copper Diet, and Radiation Therapy in Treating Patients With Glioblastoma [Completed]
RATIONALE: Penicillamine may stop the growth of glioblastomas by stopping blood flow to the tumor. A diet low in copper may interfere with the growth of brain tumor cells. Radiation therapy uses high-energy x-rays to damage tumor cells. Combining these therapies may be effective in treating glioblastoma. PURPOSE: Phase II trial to study the effectiveness of penicillamine, a low copper diet, and radiation therapy in treating patients who have newly diagnosed glioblastoma.

Study to Assess Long-Term Outcomes of Trientine in Wilson Disease Patients Withdrawn From Therapy With d-Penicillamine [Not yet recruiting]
A study to review Wilson disease patients who have previously been prescribed d- Penicillamine but were changed to trientine as treatment for their disease, and to follow them for a further 12 months.

Effect of Increasing Doses of Cystine Binding Thiol Drugs on Cystine Capacity in Patients With Cystinuria [Recruiting]
The purpose of this study is to evaluate the effect of escalating doses of cystine biding thiol drugs, including tiopronin and d-penicillamine, on the urinary cystine capacity, which is a measure of the amount of cystine in the urine, in patients with cystinuria. The overall goal will be to help guide therapy and ultimately minimize unnecessary side effects caused by larger doses.

Cystine Capacity Clinical Study (CysCap) [Recruiting]
The purpose of this study is to determine whether urinary cystine capacity, an assay used to measure the amount of cystine in the urine, can be used to predict stone recurrence in patients with cystinuria.

more trials >>


Page last updated: 2016-06-21

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2015